内在电活动驱动小细胞肺癌的进展
Paola Peinado1, Marco Stazi1, Claudio Ballabio1
1Cancer Neuroscience Laboratory, Francis Crick Institute, London, UK.
Nature
|February 12, 2025
概括
小细胞肺癌 (SCLC) 中的神经内分泌 (NE) 细胞具有电刺激性,驱动瘤恶性病变和转移. 这些NE细胞完全依赖于氧化化,由非NE细胞支持,形成一个自我维持的瘤循环.
科学领域:
- 癌症生物学
- 神经科学
- 代谢调节
背景情况:
- 神经受体和神经内分泌 (NE) 转化与癌症进展有关.
- 在癌细胞中, 电刺激是神经元的一个关键特征,
- 小细胞肺癌 (SCLC) 是一种具有明显NE和非NE细胞亚群的侵袭性NE癌症.
研究的目的:
- 研究电刺激性在SCLC中的存在和作用.
- 了解SCLC中NE和非NE细胞之间的代谢相互作用.
- 探索SCLC进展,内化和神经元特征之间的关系.
主要方法:
- 电生理记录以评估NE细胞的刺激性.
- 代谢试验以确定能量依赖性 (氧化酸化与糖解).
- 瘤内化和SCLC细胞神经标记在进展过程中的分析.
主要成果:
- 但非NE细胞却表现出电刺激性和动作潜力的激发,从而促进SCLC恶性瘤的发生.
- 与典型的癌细胞糖解相反,NE细胞对氧化酸化有着不寻常的依赖.
- 非NE细胞为NE细胞提供代谢支持,类似于天体细胞与神经元的相互作用.
- 在SCLC的进展过程中,癌细胞内置变化,内异质性增加,神经元特征增强.
结论:
- 癌细胞内在的电活动驱动SCLC恶性和转移潜力.
- 由电活动和代谢支持推动的瘤自主恶性循环促进长期瘤形成.
- 针对电刺激或代谢依赖可能为SCLC提供新的治疗策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
The Intrinsic Apoptotic Pathway
6.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.1K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


